Navigation Links
Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc.
Date:8/6/2008

BioTime, Inc. (OTCBB:BTIM) announced today that Robert N. Butler, M.D., has been elected to BioTime’s Board of Directors. Dr. Butler is the founder, Chief Executive Officer, and President of the International Longevity Center-USA, a non-profit international research, policy, and education organization formed to educate individuals on how to live longer and better, and advise society on how to maximize the benefits of today's age boom. Dr. Butler received his B.A. degree from Columbia College in 1949 and a M.D. Degree from the College of Physicians and Surgeons of Columbia University in 1952. He was the founding director of the National Institute on Aging of the National Institutes of Health, and from 1975-1982 he led that institute educating the nation about the need for innovative therapies for Alzheimer’s disease. At the Mount Sinai School of Medicine, he founded the nation’s first department of geriatrics where he is Professor of Geriatrics and Adult Development. He is a member of the Institute of Medicine of the National Academy of Sciences and of the National Academy of Social Insurance. He was a member of the Physician Payment Review Commission, an agency of the U.S. Congress, from 1986-89. He is a founding Fellow of the American Geriatrics Society and vice chairman of the Alliance for Aging Research. He served as Chair, Advisory Committee, 1995, for the White House Conference on Aging. He was a member of the Advisory Committee for the Project on Death in America by the Open Society Institute. He has been a consultant to the U.S. Senate Special Committee on Aging, the Commonwealth Fund, the Brookdale Foundation, the Donald W. Reynolds Foundation and numerous other organizations. He has served on the National Advisory Committees of the Physicians for Human Rights, the National Women's Health Resource Center and the Mildred and Claude Pepper Foundation, among other organizations. He also served as medical editor-in-chief of Geriatrics, a journal for primary care physicians, for 14 years and has authored approximately 300 scientific and medical articles. Dr. Butler won the Pulitzer Prize for his book Why Survive? Being Old in America. His latest book is The Longevity Revolution.

ALAMEDA, Calif. (Business Wire EON) August 6, 2008 -- "The aging of the baby boom generation is the most significant demographic trend of our time," said Michael D. West, Ph.D., BioTime's Chief Executive Officer. "We look forward in working with Dr. Butler in focusing the emerging technologies of regenerative medicine on the large and growing markets in age-related degenerative disease."

  • Butler said, "It is exciting to be elected to the board of BioTime, an innovative company built for this era of longevity."

About BioTime, Inc. (BTIM.OB):

BioTime, headquartered in Alameda, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Additional information about BioTime can be found on the web at www.biotimeinc.com. Hextend, PentaLyte, HetaCool, EmbryomicsTM, ESpyTM, and ESpanTM are trademarks of BioTime, Inc.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.


Read the full story at http://www.prweb.com/releases/biotime/butler/prweb1188094.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
2. Immunotec Inc. announces retirement of President & CEO C.H. (Chuck) Roberts
3. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
4. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
5. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
6. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
7. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
8. WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
9. Hiemstra Appoints Robert C. Glines as Director of Business Development
10. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
11. Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc. 
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
Breaking Biology News(10 mins):